+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients

Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients

Plos One 9(7): E102764

Breast cancer prognosis and treatment is highly dependent on the molecular features of the primary tumors. These tumors release specific molecules into the environment that trigger characteristic responses into the circulatory cells. In this study we investigated the expression pattern of 84 genes known to be involved in breast cancer signaling in the peripheral blood of breast cancer patients with ER-, PR- primary tumors. The patients were grouped according to Her2 expression on the primary tumors in Her2+ and Her2- cohorts. Transcriptional analysis revealed 15 genes to be differentially expressed between the two groups highlighting that Her2 signaling in primary tumors could be associated with specific blood gene expression. We found CCNA1 to be up-regulated, while ERBB2, RASSF1, CDH1, MKI67, GATA3, GLI1, SFN, PTGS2, JUN, NOTCH1, CTNNB1, KRT8, SRC, and HIC1 genes were down-regulated in the blood of triple negative breast cancer patients compared to Her2+ cohort. IPA network analysis predicts that the identified genes are interconnected and regulate each other. These genes code for cell cycle regulators, cell adhesion molecules, transcription factors or signal transducers that modulate immune signaling, several genes being also associated with cancer progression and treatment response. These results indicate an altered immune signaling in the peripheral blood of triple negative breast cancer patients. The involvement of the immune system is necessary in favorable treatment response, therefore these results could explain the low response rates observed for triple negative breast cancer patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052614051

Download citation: RISBibTeXText

PMID: 25068292

DOI: 10.1371/journal.pone.0102764

Related references

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. Bmc Cancer 10: 56, 2010

Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. Breast Cancer 23(4): 624-632, 2017

HER2 expression in disseminated tumor cells (DTC) and corresponding primary tumors of breast cancer patients. Journal of Clinical Oncology 23(16_suppl): 9580-9580, 2016

Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. Breast Cancer 2018, 2018

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. Bmc Cancer 15: 39, 2016

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagnostic Molecular Pathology 18(1): 22-29, 2009

Influence of estrogen receptor expression on HER2 mRNA levels in HER2-gene amplified breast cancer tumors as measured using FISH and. 2007

Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cellular Oncology 32(5-6): 361-372, 2010

Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. Anticancer Research 35(7): 4023-4036, 2015

Differential Gene Expression of BRCA1,ERBB2 and TP53 biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry 16(4): 519-525, 2016

Microarray analysis of differential gene expression profile in peripheral blood cells of patients with human essential hypertension. International Journal of Medical Sciences 8(2): 168-179, 2011

AB0191 Gene and Protein Expression Profile of Peripheral Blood in Primary Sjogren's Syndrome Patients. Annals of the Rheumatic Diseases 73(Suppl 2): 866-866, 2014

Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts). Journal of Clinical Oncology 26(15_suppl): 1019-1019, 2016

GW26-e0264 Microarray analysis of differential gene expression profile in the peripheral blood cells of the patients with myocardial infarction. Journal of the American College of Cardiology 66(16): C155-C156, 2015

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. Bmc Cancer 16: 522, 2017